<SEC-DOCUMENT>0001437749-19-001355.txt : 20190125
<SEC-HEADER>0001437749-19-001355.hdr.sgml : 20190125
<ACCEPTANCE-DATETIME>20190125172613
ACCESSION NUMBER:		0001437749-19-001355
CONFORMED SUBMISSION TYPE:	8-K/A
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20181120
ITEM INFORMATION:		Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190125
DATE AS OF CHANGE:		20190125

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MILESTONE SCIENTIFIC INC.
		CENTRAL INDEX KEY:			0000855683
		STANDARD INDUSTRIAL CLASSIFICATION:	ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
		IRS NUMBER:				133545623
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14053
		FILM NUMBER:		19543354

	BUSINESS ADDRESS:	
		STREET 1:		220 SOUTH ORANGE AVENUE
		CITY:			LIVINGSTON
		STATE:			NJ
		ZIP:			07039
		BUSINESS PHONE:		(973) 535-2717

	MAIL ADDRESS:	
		STREET 1:		220 SOUTH ORANGE AVENUE
		CITY:			LIVINGSTON
		STATE:			NJ
		ZIP:			07039

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MILESTONE SCIENTIFIC INC/NJ
		DATE OF NAME CHANGE:	19970409

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	U S OPPORTUNITY SEARCH INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K/A
<SEQUENCE>1
<FILENAME>mlss20190125_8ka.htm
<DESCRIPTION>FORM 8-K/A
<TEXT>
<html>
<head>
	<title>mlss20190125_8k.htm</title>

	<!-- Created by RDG HTML Converter v1.1.0.0 1/25/2019 1:27:30 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no"/>
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 14pt; margin: 0pt; text-align: center;"><b>U</b><b>NITED STATES </b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 14pt; margin: 0pt; text-align: center;"><b>SECURITIES AND EXCHANGE COMMISSION</b>&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 12pt; margin: 0pt; text-align: center;"><b>Washington, D.C. 20549</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:18pt;margin:0pt;text-align:center;"><b>FORM 8-K</b><b>/A</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:18pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 12pt; margin: 0pt; text-align: center;"><b>CURRENT REPORT<br>
Pursuant to Section&nbsp;13 </b><b>o</b><b>r 15(d) of </b><b>t</b><b>he Securities Exchange Act of 1934</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Date of Report (Date of earliest event reported): </b><b>November 20</b><b>, 20</b><b>1</b><b>8</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:24pt;margin:0pt;text-align:center;"><b>Milestone</b><b> </b><b>Scientific</b><b> Inc.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Exact name of registrant as specified in its charter)</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align: bottom; width: 33%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: bottom; width: 33%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: bottom; width: 33%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Delaware</b><br>
			(State or other jurisdiction<br>
			of incorporation)</p>
			</td>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>00</b><b>1</b><b>-</b><b>14053</b><br>
			(Commission<br>
			File Number)</p>
			</td>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>13-3545623</b><br>
			(IRS Employer<br>
			Identification No.)</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>220 South Orange Avenue, </b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Livingston Corporate Park</b><b>&nbsp;</b><br>
			<b>Livingston, New Jersey</b><br>
			(Address of principal executive offices)</p>
			</td>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>07034</b><b>0</b><br>
			(Zip Code)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Registrant&rsquo;s telephone number, including area code <b>(</b><b>973) 535-2717</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Former name or former address, if changed since last report.)</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#9744; Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#9744; Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#9744; Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#9744; Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 14pt; margin-bottom: 0pt; margin-left: 30.6pt; margin-top: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:30.6pt;margin-top:0pt;text-align:left;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 30.95pt;text-align:center;">Emerging growth company &#9744;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:30.6pt;margin-right:0pt;margin-top:0pt;text-align:left;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act &#9744;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:30.6pt;margin-right:0pt;margin-top:0pt;text-align:center;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Item 3.01 &mdash; Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing </b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;">As previously reported, on November 20, 2018, Milestone Scientific Inc. (&ldquo;the Company&rdquo;) received a letter from NYSE American LLC (the &ldquo;Exchange&rdquo;) stating that the Company was not in compliance with the continued listing standards as set forth in Section(s) 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide (the &ldquo;Company Guide&rdquo;).</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;">On December 20, 2018, the Company submitted a plan of compliance (the &ldquo;Plan&rdquo;) to the Exchange addressing how it intends to regain compliance with Section(s) 1003(a)(i), (ii) and (iii) of the Company Guide by May 20, 2020. On January 24, 2019, the Company received a letter from the Exchange stating that the Company&rsquo;s Plan has been accepted by the Exchange. The Company is still not in compliance with Section(s) 1003(a)(i), (ii) and (iii) of the Company Guide and its listing on the Exchange is being continued pursuant to an extension granted by the Exchange. If the Company is not in compliance with the continued listing standards by May 20, 2020, or if the Company does not make progress consistent with the Plan, the Exchange will initiate delisting procedures as appropriate. The Company may appeal a staff delisting determination in accordance with Section 10 and Part12 of the Company Guide.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;"><b>Item 8.01 &mdash; Other Events. </b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;">On January 25, 2019, the Company issued a Press Release announcing that the Exchange has accepted the Company&rsquo;s Plan. A copy of the Press Release is attached to this Current Report as Exhibit 10.1 and is incorporated into this Item 8.01 by reference.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;"><b>Item 9.01 &mdash; Financial Statements and Exhibits. </b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;">(d) Exhibits</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;">Exhibit No.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Description</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;">10.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="ex_133442.htm" style="-sec-extract:exhibit;">Press Release, dated January 25, 2019</a></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>SIGNATURES </b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td colspan="3" style="vertical-align: middle; width: 3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-transform:uppercase;"><b>Milestone Scientific</b><b> Inc.<br>
			&nbsp;</b></p>
			</td>
			<td style="vertical-align: middle; width: 13%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Dated: January 25, 2019&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By:&nbsp;&nbsp;</p>
			</td>
			<td colspan="2" style="vertical-align:middle;border-bottom:solid 1px #000000;;width:34%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/ Joseph D&rsquo;Agostino</p>
			</td>
			<td style="vertical-align: middle; width: 13%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td colspan="2" style="vertical-align:middle;width:34%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Joseph D&rsquo;Agostino&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 13%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:middle;width:34%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Chief Financial Officer</p>
			</td>
			<td style="vertical-align: middle; width: 13%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex_133442.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html>
<head>
	<title>ex_133440.htm</title>

	<!-- Created by RDG HTML Converter v1.1.0.0 1/25/2019 1:30:51 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no"/>
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 10.1</b></font></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font><img src="msci.jpg"></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Contact:</b><br>
David Waldman or Natalya Rudman<br>
Crescendo Communications, LLC<br>
Email: <u>mlss@crescendo-ir.com</u><br>
Tel: 212-671-1020</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><font style="font-family:'Times New Roman',Times,Serif;font-size:11pt;"><b>New York Stock Exchange Accepts </b><b>Milestone Scientific&rsquo;s</b><b> Plan to Regain Compliance</b><b> </b></font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>LIVINGSTON, NJ, </b><b>January 25, 2019</b><b> -- </b><b>Milestone Scientific Inc</b><b>. (</b><b>NYSE</b><b>: </b><b>MLSS</b><b>)</b>, a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that the New York Stock Exchange has accepted the Company&rsquo;s plan to regain compliance with the NYSE American&rsquo;s stockholder&rsquo;s equity continued listing standards as set forth in Section(s) 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide (the &ldquo;Company Guide&rdquo;). As previously disclosed, the NYSE American LLC (the &ldquo;Exchange&rdquo;) notified the Company on November 20, 2018, that it was not in compliance with the NYSE American&#39;s continued listing standards.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Based upon a review of the compliance plan and information submitted by the Company, the Exchange determined that the Company made a reasonable demonstration of its ability to make substantial progress toward regaining compliance with Section(s) 1003(a)(i), (ii), and (iii) of the Company Guide by May 20, 2020. While the Company is still not compliance with the Exchange&rsquo;s continued listing standards, its listing on the Exchange is being continued pursuant to an extension granted by the Exchange.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The Company will be subject to periodic review by the Exchange staff during the period covered by the plan. Failure to make progress consistent with the plan or to regain compliance with the continued listing standards by May 20, 2020 could result in the Company&rsquo;s shares being delisted from the Exchange. The Company may appeal a staff delisting determination in accordance with Section 10 and Part12 of the Company Guide.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i><b>&nbsp;</b></i></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i><b>About Milestone Scientific Inc.</b></i></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i><b>&nbsp;</b></i></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Milestone Scientific Inc. (MLSS) is a medical device company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone&#39;s computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone&rsquo;s proprietary <i>DPS</i> Dynamic Pressure Sensing technology<sup>&reg;</sup> is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections. For more information please visit our website: www.milestonescientific.com.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Safe Harbor Statement</b></i></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>&nbsp;</b></i></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>This press release contains forward-looking statements regarding the timing and financial impact of Milestone&#39;s ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone&#39;s control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone&#39;s periodic filings with the Securities and Exchange Commission, including without limitation, Milestone&#39;s Annual Report for the year ended December 31, </i><i>201</i><i>7</i><i>. The forward looking statements in this press release are based upon management&#39;s reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.</i></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>&nbsp;</i></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"># # #</p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>msci.jpg
<TEXT>
begin 644 msci.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !> /H# 2(  A$! Q$!_\0
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MW9_B_'K7DX#%N6+A5BW>ZO\ >?7<>Y'# X2-)*/+'2/+>]K=;M]NFGDC@_\
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M=[>G&FXVY=M2:=)0DY7W/P]^)_QYT/5/^"LZ>.($UUO"<7B&.<WK:-=JK1B
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M#O[+G_!.?5_ -]%JUQXH\;Z2]M865AIL]P=K84N[HA1%'/WB">P-?57[+?\
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61110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
